GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma.
{iframe}http://www.foxnews.com/health/2016/07/27/gsk-chases-next-biotech-asthma-drug-with-230m-j-j-deal.html{/iframe}